• Publications
  • Influence
Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo.
The data show that insulin stimulates both in vitro and in vivo ET-1 secretion, suggesting that such interaction could play a significant role in the development of atherosclerotic lesions in hyperinsulinemic conditions.
Plasma Endothelin-1 Levels in Obese Hypertensive and Normotensive Men
It is shown that plasma ET-1 concentrations are increased in human obesity, which could depend on fasting insulin concentrations, abnormal peptide clearance, or both, and Hypertension does not influence the behavior of plasmaET-1 levels in obese men.
Endogenous Insulin Modulates Circulating Endothelin-1 Concentrations in Humans
This study indicates that significant changes in circulating ET-1 levels occur after oral glucose loading, probably due to a glucose-induced increment in endogenous insulin concentration.
Circulating endothelin-1 concentrations in patients with chronic hypoxia.
Chronic hypoxia may be regarded as an important stimulus for endothelin-1 release and as one of the main contributors to increased vasoconstriction in the vascular pulmonary bed which often accompanies lung disease.
Effect of ACE Inhibition on Spontaneous and Insulin-Stimulated Endothelin-1 Secretion: In Vitro and In Vivo Studies
In vivo, captopril inhibits both spontaneous and insulinstimulated ET-1 secretion by endothelial cells, acting on angiotensin-converting enzyme bound to the luminal cell side, as well as in vitro and in vivo.
Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities.
An early endothelial activation was present in essential hypertensive patients with impaired glucose tolerance, regardless of the presence of hyperlipidemia, and ACE inhibition counteracted such endothelialactivation.
Early upregulation of endothelial adhesion molecules in obese hypertensive men.
It is shown that obesity per se induces early endothelial activation in hypertensive and normotensive men and weight loss counteracted endothelialactivation in both obese hypertensive or normotense men.
Circulating endothelin-1 levels in obese patients with the metabolic syndrome.
We evaluated venous plasma ET-1 concentrations in 18 never-treated obese men (body mass index 31.0 +/- 0.5 kg/m2; age 45.4 +/- 4.3 years) showing the whole features of the above syndrome and 12
Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels.
The findings indicate that angiotensin II regulates endothelin-1 release by cultured endothelial cells through an AT1 receptor-dependent pathway, but does not influence circulating endothelins-1 levels in vivo.